

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Boronat et al.
Filed : August 6, 2001
Serial No. : 09/921,992
Title : Methyl-D-Erythritol Phosphate Pathway Genes
Examiner : Stuart Baum
Group Art Unit: 1638
Atty Docket : REN-00-084-US (16516.107)

FAX RECEIVED

JUL 31 2003

GROUP 1600

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
via Facsimile **ONLY**
Ex. S Baum 703-305-3014 (fax) 3 pages
703-305-6997 (phone)


TRANSMITTAL LETTER

Dear Sir:

Please find enclosed for the above-referenced application the following:

- 1) a Revised Response to Restriction Requirement.


Respectfully submitted,


Donald J. Silvert, Reg. No. 37,552
Lois Ruszala, Reg. No. 39,074
Thomas E. Omholt, Reg. No. 37,052
Attorney for Applicants

Renessen LLC
Legal Dept-Intellectual Property
3000 Lakeside Dr., Suite 300-South
Bannockburn, IL 60015
Phone Contact: 847-457-5130
Fax: 847-457-5174

CERTIFICATE OF FACSIMILE

I hereby certify that the foregoing document is being sent by facsimile to Commissioner for Patents, to the attention of Examiner Stuart Baum at 703-305-3014 on this 25th day of July, 2003.


Darlene Rentschler / Sapara Paulov

#10
Rosen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Boronat et al.
Filed : August 6, 2001
Serial No. : 09/921,992
Title : Methyl-D-Erythritol Phosphate Pathway Genes
Examiner : Stuart Baum
Group Art Unit : 1638
Atty Docket : REN-00-084-US (16516.107)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Revised Response to Restriction Requirement

Sir:

In response to the Office Action mailed June 26, 2003, Paper No. 9, Applicants submit the following response.

Remarks


The application presently contains claims 1-10. In the Office Action mailed June 26, 2003, the Examiner indicated that the amendment filed on 4/18/2003 was non-responsive for electing SEQ ID NO: 3 and SEQ ID NO: 48. The Examiner indicated that applicants were required to elect a corresponding pair of sequences, and found that SEQ ID NO: 3 and SEQ ID NO: 48 were not such sequences.

Applicants thank the Examiner for providing applicants with the time to supply the omission or correction.

Applicants maintain the traverse of the restriction requirement for the reasons set forth in their amendment dated April 18, 2003. However, in order to facilitate prosecution, Applicants have provisionally elected, with traverse, Group I, Claims 1-5 and 7-9 and further have

CERTIFICATE OF FACSIMILE

I hereby certify that the foregoing document is being sent by facsimile to Commissioner for Patents, to the attention of Examiner Stuart Baum at 703-305-3014 on this 25th day of July, 2003.


Darlene Rentschler / Sandra Paulov


Sai S. SUBRAMANIAM et al.
Appl. No. 09/688,069

provisionally elected, with traverse, nucleic acid sequence SEQ ID NO: 3 and amino acid sequence SEQ ID NO: 78.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in the documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account Number 50-1100, referencing docket number 16516.107. Applicants likewise authorize a charge to Deposit Account Number 50-1100 for any other fees related to the present application that are not otherwise provided for in the accompanying documents.

Should the Examiner have any questions regarding this application, the Examiner is encouraged to contact Applicants' undersigned representative at (847) 457-5055.

Respectfully submitted,


Donald J. Silvert, Reg. No. 37,552
Lois Ruzala, Reg. No. 39,074
Thomas E. Omholt, Reg. No. 37,052
Attorney for Applicants

Renessen LLC
Legal Dept-Intellectual Property
3000 Lakeside Dr., Suite 300-South
Bannockburn, IL 60015
Phone Contact: 847-457-5130
Fax: 847-457-5174